

DAFTAR PUSTAKA

1. Kemenkes RI. Profil Kesehatan Indonesia 2018 [Indonesia Health Profile 2018]. 2019. 207 p.
2. Zahnia S, Sumekar DW, Kedokteran F, Lampung U, Ilmu B, Komunitas K, et al. Kajian Epidemiologis Skizofrenia Epidemiologic Study of Schizophrenia. 2013;
3. Riskesdas K. Hasil Utama Riset Kesehatan Dasar (RISKESDAS). *J Phys A Math Theor.* 2018;44(8):1–200.
4. Puspitasari AW, Angeline L. Analisis Potensi Interaksi Obat Golongan Antidepresan pada Pasien Skizofrenia di Rumah Sakit Jiwa Dr. Soeharto Heerdjan Tahun 2016. *Pharm Sci Res.* 2019;6(1):13–20.
5. Sedjahtera K. Hubungan Lama Terapi Antipsikotik dengan Kadar SGOT dan SGPT pada Pasien Skizofrenia. *J FK Unand.* 2013;6(1):128–33.
6. Yunusa I, El Helou ML. The Use of Risperidone in Behavioral and Psychological Symptoms of Dementia: A Review of Pharmacology, Clinical Evidence, Regulatory Approvals, and Off-Label Use. *Front Pharmacol.* 2020;11(May):1–7.
7. Heriza M, Fikri M, Handayani L. Pencarian Hubungan Adverse Event pada Obat Penenang dengan Apriori. *J CoreIT J Has Penelit Ilmu Komput dan Teknol Inf.* 2016;2(2):22.
8. Collaborating N, Health M. The Nice Guideline on the Treatment and Management of Depression. London: The British Psychological Society and The Royal College of Psychiatrists; 2019.
9. Rahmi A. Potensi Interaksi Obat Antipsikotik pada Pasien Skizofrenia Paranoid Rawat Jalan di RSJ Prof. Dr. HB Saanin Padang Tahun 2015. 2017;
10. Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Gatti G, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction. *J Clin Psychopharmacol.* 2002;22(4):419–23.
11. Fluoxetine / risperidone interaction. 2018;(2):9954.
12. Stockley IH. Stockley 's Drug Interactions. ninth. Pharmaceutical Press. London: Pharmaceutical Press; 2010. 1801 p.
13. Lamtiar Parulian, Ening Listyanti, Anita Kumala Hati IS. Analisis Hubungan Polifarmasi Dan Interaksi Obat Pada Pasien Rawat Jalan yang Mendapat Obat Hipertensi di RSP. Dr. Ario Wirawan Periode Januari-Maret 2019. *Indones J Pharm Nat Prod.* 2019;02(July):79–86.
14. Amelia Lorensia RIW. Hubungan Jumlah Obat Yang Digunakan Terhadap

- Risiko Terjadinya Drug-Related Problems Pada Pasien Asma di Suatu Rumah Sakit Di Surabaya. *J Trop Pharm Chem*. 2016;3(3).
15. Valverde IAPM, da Silva MJS, Retto MPF. Association between potential drug interactions and clinical outcomes in hematopoietic stem cell transplantations. *J Oncol Pharm Pract*. 2019;25(5):1105–11.
 16. Gitawati R. Interaksi Obat dan Beberapa Implikasinya. *Media Litbang Kesehatan*. 2008;XVIII.
 17. Ramdini DA, Sumiwi SA, Barliana MI, Destiani DP, Nur IL. Potensi Interaksi Obat pada Pasien Skizofrenia di Salah Satu Rumah Sakit Jiwa di Provinsi Jawa Barat Potential Drug Interactions on Schizophrenic Patients at a Mental Hospital in West Java , Indonesia. 2018;7(4).
 18. Palleria C, Di Paolo A, Giofrè C, Caglioti C, Leuzzi G, Siniscalchi A, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. *J Res Med Sci*. 2013;18(7):600–9.
 19. Id JH, Eiermann B, Kimland E, Mannheimer B. Prevalence of potential drug-drug interactions in Swedish pediatric outpatients. 2019;1–17.
 20. Martinbiancho J, Zuckermann J, Dos Santos L, Silva MM. Profile of Drug Interactions in Hospitalized Children. *Pharm Pract (Granada)*. 2007;5(4):157–61.
 21. Baxter K. Stockley ' s Drug Interactions. 8th ed. Great Britain: Pharmaceutical Press is; 2008.
 22. Mozayani A dan LPR. *Buku Ajar Interaksi Obat Pedoman Klinis dan Forensik*. Jakarta: Penerbit Buku Kedokteran; 2014.
 23. Handayani FW, Muhtadi A, Farmasi F, Padjadjaran U, Dara T, Manis K, et al. Identifikasi Potensi Interaksi antar Obat pada Resep Umum di Apotek Kimia Farma 58 Kota Bandung Bulan April 2019. *Farmaka*. 2013;4(April):1–15.
 24. Ismail M, Iqbal Z, Khatkhat MB, Javaid A, Khan MI, Khan TM, et al. Potential drug-drug interactions in psychiatric ward of a tertiary care hospital: Prevalence, levels and association with risk factors. *Trop J Pharm Res*. 2012;11(2):289–96.
 25. Picchioni MM, Murray RM. *Schizophrenia*. 2007;335(July):91–5.
 26. Patel KR, Cherian J, Gohil K. *Schizophrenia : Overview and Treatment Options*. 2014;39(9):638–45.
 27. Sie M. *Schizophrenia clinical features and diagnosis*. *Clin Pharm*. 2011;3(1):41–4.
 28. Abuse D of MH and P of S, Organization WH. *For Mental Health and Schizophrenia and Public Health*. Geneva: WHO; 1998.
 29. Abuse S. *Impact of the DSM-IV to DSM-5 Changes on yhe N National*

- Survey On Drug Use and Health. 2016;(June).
30. Association AP. Diagnostic and Statistical Manual of Mental Disorder Fifth Edition DSM-5 TM. 5th ed. American Psychiatric Association. Washington, DC: American Psychiatric Publishing; 2013. 461–462 p.
 31. Mousavi SG, Rostami H, Sharbafchi MR, Boroujeni AS. Journal of Research in Pharmacy Practice Onset of action of atypical and typical antipsychotics in the treatment of acute psychosis. 2013;(October).
 32. Tamminga CA. Pharmacological aspects. 1990;281–6.
 33. Weells BG, DiPiro JT, Schwinghammer TL, Dipiro C V. Pharmacotherapy Handbook. 9th ed. AIAA Guidance, Navigation, and Control Conference. US: Mc Graw Hill Education; 2015.
 34. B S. Antidepressants: Mechanism of Action, Toxicity and Possible Amelioration. J Appl Biotechnol Bioeng. 2017;3(5).
 35. Ables AZ. Antidepressants : Update. 2015;(March 2003).
 36. Gelenberg AJ, Freeman MP, Markowitz JC, Rosenbaum JF, Thase ME, Trivedi MH, et al. Treatment of Patients With Major Depressive Disorder. 2010;(May).
 37. Indonesia KKR. Farmakope Indonesia Edisi 5. Kemenkes RI. 2014.
 38. Disease N. Clinical Utility of the Risperidone Formulations in the Management of Schizophrenia. 2011;
 39. Schoenwald RD. Pharmacokinetics in Drug Discovery and Development. Florida: CRC Press; 2002.
 40. Janssen Pharmaceutica Product LP. Risperdal® (Risperidone) Tablets/Oral Solution Risperdal®.
 41. Hydrochloride F. Fluoxetine hydrochloride. (10):1–29.
 42. Nadeem P, Alam MS, Alam O, Andalip M, Azad B. Fluoxetine : Pharmacological and Computational Study Fluoxetine : Pharmacological and Computational Study Abstract Pharmacokinetics. 2011;2(3):1–7.
 43. Ferreira JC, Patino CM. Types of outcomes in clinical research. J Bras Pneumol. 2017;43(1):5.
 44. Andira S, Nuralita NS. Pengaruh Perbedaan Jenis Kelamin terhadap Simtom Depresi Pasien Skizofrenia di Rumah Sakit Jiwa Prof . Dr . M . Ildrem Kota Medan Sumatera Utara Pada Tahun 2017. 2018;3(2):97–108. Available from:
http://jurnal.umsu.ac.id/index.php/buletin_farmatera/article/view/1946/2005
 45. Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender Differences in Schizophrenia and First-Episode Psychosis: A Comprehensive Literature Review. Schizophr Res Treatment. 2012;2012:1–9.

46. Rahaya A, Cahaya N. Studi Retrospektif Penggunaan Trihexyfenidil Pada Pasien Skizofrenia Rawat Inap Yang Mendapat Terapi Antipskotiik Di Rumah Sakit Jiwa Sambang Lihum. *J Farm Galen (Galenika J Pharmacy)*. 2016;2(2):124–31.
47. D.S E. Buku Ajar Psikiatri. Jakarta: Fakultas Kedokteran Universitas Jakarta; 2013.
48. Yulianty MD, Cahaya N, Srikartika VM. Studi Penggunaan Antipsikotik dan Efek Samping pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum Kalimantan Selatan. *J Sains Farm Klin* [Internet]. 2017;3(2):153–64. Available from: <http://jsfkonline.org/index.php/jsfk/article/view/108>
49. Dania H, Faridah IN, Rahmah KF, Abdulah R, Barliana MI, Perwitasari DA. Hubungan Pemberian Terapi Antipsikotik terhadap Kejadian Efek Samping Sindrom Ekstrapiramidal pada Pasien Rawat Jalan di Salah Satu Rumah Sakit di Bantul, Yogyakarta. *Indones J Clin Pharm*. 2019;8(1).
50. Health M. Schizophrenia Overview. 2020. p. 1–4.
51. Gogtay N, Vyas NS, Testa R, Wood SJ, Pantelis C. Age of onset of schizophrenia: Perspectives from structural neuroimaging studies. *Schizophr Bull*. 2011;37(3):504–13.
52. Handayani L, Febriani F, Rahmadanni A, Saufi A. Faktor Risiko Kejadian Skizofrenia Di Rumah Sakit Jiwa Grhasia Daerah Istimewa Yogyakarta (Diy). *Humanitas (Monterey N L)*. 2017;13(2):135.
53. Utami R, Puji Rahayu P. Hubungan Lama Hari Rawat Dengan Tanda Dan Gejala Serta Kemampuan Pasien Dalam Mengontrol Halusinasi. *J Keperawatan Jiwa*. 2018;6(6):106–15.
54. Andari S. Pelayanan Sosial Panti Berbasis Agama dalam Merehabilitasi Penderita Skizofrenia Religious Based Social Services on Rehabilitation of Schizophrenic Patients. *J PKS*. 2017;16(2):195–208.
55. Yogeswary K. Schizoaffective Disorder : An overview. *Int J Clin Psychiatry*. 2014;2(1):11–5.
56. Rades M, Wulan AJ. Skizoafektif Tipe Campuran Schizoaffective Disorder Mixed Type. 2016;5 No 2:58–62.
57. Hooten RSDWM. Extrapyramidal Symptoms [Internet]. 2020 [cited 2021 Jan 14]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK534115/>
58. Tandon R, Jibson M. Extrapyramidal Side Effects of Antipsychotic Treatment: Scope of Problem and Impact on Outcome. *Ann Clin Psychiatry*. 2002;14(2):123–9.
59. Novitayani S, Keilmuan B, Jiwa K, Keperawatan F, Syiah U, Banda K. Terapi Psikofarmaka Pada Pasien Rawat Jalan Di Rumah Sakit Jiwa Aceh. *Idea Nurs J*. 2018;9(1).
60. Spina E, De Leon J. Metabolic drug interactions with newer antipsychotics:

A comparative review. *Basic Clin Pharmacol Toxicol.* 2007;100(1):4–22.

61. Feri Setiadi, Shirly Kumala, Hesty Utami R AS. Analisis Faktor-Faktor yang Mempengaruhi Outcome Terapi Pasien Pneumonia di Rumah Sakit Umum Pusat Fatmawati Jakarta. *Heal Tadulako J (Jurnal Kesehat Tadulako).* 2019;5(1):1–80.
62. Harrow M, Grossman LS, Herbener ES, Davies EW. Ten-year outcome: Patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. *Br J Psychiatry.* 2000;177(NOV.):421–6.
63. Rahmawati F, Handayani R, Gosal V. Kajian retrospektif interaksi obat di Rumah Sakit Pendidikan Dr. Sardjito Yogyakarta A retrospective study on drug interactions in Dr. Sardjito Hospital Yogyakarta. *Fita Rahmawati Maj Farm Indones.* 2006;17(4):177–83.
64. Herdaningsih S, Muhtadi A, Lestari K, Annisa N. Potensi Interaksi Obat-Obat pada Resep Polifarmasi: Studi Retrospektif pada Salah Satu Apotek di Kota Bandung. *J Farm Klin Indones.* 2016;5(4):288–92.
65. Ih H, Putri RA, Untari EK. Perbedaan Jenis Terapi Antipsikotik terhadap Lama Rawat Inap Pasien Skizofrenia Fase Akut di RSJD Sungai Bangkong Pontianak Hariyanto. *Indones J Clin Pharm.* 2016;5(2):115–22.
66. Dhanya T, Gangadhar R, Subha N. Clinical and economic outcomes of risperidone versus clozapine in the treatment of chronic schizophrenia. *Int J Basic Clin Pharmacol.* 2015;4(6):1080–5.

